{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Disease-modifying+anti-rheumatic+drugs", "query": { "intervention": "Disease-modifying anti-rheumatic drugs" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 72, "total_pages": 8, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Disease-modifying+anti-rheumatic+drugs&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-08T07:14:35.002Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01313208", "title": "Moderate Rheumatoid Arthritis (RA) With Etanercept (Enbrel)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "etanercept", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "DMARD Therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 210, "start_date": "2011-03", "completion_date": "2013-05", "has_results": true, "last_update_posted_date": "2017-02-09", "last_synced_at": "2026-10-08T07:14:35.002Z", "location_count": 38, "location_summary": "Birmingham, Alabama • Tuscaloosa, Alabama • Peoria, Arizona + 34 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tuscaloosa", "state": "Alabama" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Encino", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01313208" }, { "nct_id": "NCT02349295", "title": "A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Psoriatic Arthritis" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Ixekizumab 80 mg Q4W", "type": "DRUG" }, { "name": "Ixekizumab 80 mg Q2W", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 363, "start_date": "2014-12-31", "completion_date": "2019-06-26", "has_results": true, "last_update_posted_date": "2020-07-01", "last_synced_at": "2026-10-08T07:14:35.002Z", "location_count": 59, "location_summary": "Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 50 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02349295" }, { "nct_id": "NCT01202760", "title": "A Rheumatoid Arthritis Study in Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "LY2127399", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1004, "start_date": "2011-01", "completion_date": "2013-07", "has_results": true, "last_update_posted_date": "2018-04-25", "last_synced_at": "2026-10-08T07:14:35.002Z", "location_count": 77, "location_summary": "Birmingham, Alabama • Paradise Valley, Arizona • Peoria, Arizona + 74 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Paradise Valley", "state": "Arizona" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01202760" }, { "nct_id": "NCT00531817", "title": "A Study of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Tocilizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Permitted DMARDs", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 619, "start_date": "2007-10", "completion_date": "2011-03", "has_results": true, "last_update_posted_date": "2012-08-20", "last_synced_at": "2026-10-08T07:14:35.002Z", "location_count": 156, "location_summary": "Birmingham, Alabama • Montgomery, Alabama • Lake Havasu City, Arizona + 135 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Montgomery", "state": "Alabama" }, { "city": "Lake Havasu City", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00531817" }, { "nct_id": "NCT01146652", "title": "Long Term Evaluation of Sarilumab in Rheumatoid Arthritis Patients (SARIL-RA-EXTEND)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "SAR153191 (REGN88)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2023, "start_date": "2010-06-21", "completion_date": "2020-12-31", "has_results": true, "last_update_posted_date": "2022-03-28", "last_synced_at": "2026-10-08T07:14:35.002Z", "location_count": 75, "location_summary": "Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 66 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Glendale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01146652" }, { "nct_id": "NCT02057250", "title": "To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "RA" ], "interventions": [ { "name": "Sarilumab", "type": "DRUG" }, { "name": "Auto-Injector Device (AID)", "type": "DEVICE" }, { "name": "Pre-filled Syringe (PFS)", "type": "DEVICE" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Sulfasalazine", "type": "DRUG" }, { "name": "Leflunomide", "type": "DRUG" }, { "name": "Hydroxychloroquine", "type": "DRUG" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 217, "start_date": "2014-03", "completion_date": "2016-03", "has_results": true, "last_update_posted_date": "2017-06-20", "last_synced_at": "2026-10-08T07:14:35.002Z", "location_count": 31, "location_summary": "Huntsville, Alabama • Peoria, Arizona • Roseville, California + 25 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Roseville", "state": "California" }, { "city": "Boulder", "state": "Colorado" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02057250" }, { "nct_id": "NCT01490450", "title": "Psoriatic Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to NSAIDs or Non-biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Arthritis, Psoriatic" ], "interventions": [ { "name": "Placebo matching BMS-945429", "type": "BIOLOGICAL" }, { "name": "BMS-945429", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "CSL Behring", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 165, "start_date": "2011-12", "completion_date": "2015-06", "has_results": true, "last_update_posted_date": "2021-11-05", "last_synced_at": "2026-10-08T07:14:35.002Z", "location_count": 8, "location_summary": "San Diego, California • Denver, Colorado • Trumbull, Connecticut + 5 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Trumbull", "state": "Connecticut" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Jackson", "state": "Mississippi" } ], "official_url": "https://clinicaltrials.gov/study/NCT01490450" }, { "nct_id": "NCT00160693", "title": "Open Label Long-Term Safety Study of Certolizumab Pegol (CZP) for Patients With Rheumatoid Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Certolizumab Pegol", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "UCB Pharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 402, "start_date": "2003-03", "completion_date": "2011-02", "has_results": true, "last_update_posted_date": "2018-08-01", "last_synced_at": "2026-10-08T07:14:35.002Z", "location_count": 29, "location_summary": "Huntsville, Alabama • Paradise Valley, Arizona • Washington D.C., District of Columbia + 26 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Paradise Valley", "state": "Arizona" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Aventura", "state": "Florida" }, { "city": "Clearwater", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00160693" }, { "nct_id": "NCT01754935", "title": "A Magnetic Resonance Imaging Study and Arthroscopic Biopsy Substudy in Subjects With Active Rheumatoid Arthritis Receiving VX-509, an Oral JAK3 Inhibitor", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "VX-509", "type": "DRUG" }, { "name": "VX-509 matching placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 43, "start_date": "2013-01", "completion_date": "2014-02", "has_results": false, "last_update_posted_date": "2015-05-19", "last_synced_at": "2026-10-08T07:14:35.002Z", "location_count": 21, "location_summary": "Stanford, California • Upland, California • Fort Lauderdale, Florida + 18 more", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Upland", "state": "California" }, { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Venice", "state": "Florida" }, { "city": "West Palm Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01754935" }, { "nct_id": "NCT06072768", "title": "Dynamic Treatment Regiments for Glucocorticoid Tapering", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "15-day taper prednisone", "type": "DRUG" }, { "name": "150-day taper prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "VA Office of Research and Development", "sponsor_class": "FED", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 200, "start_date": "2023-03-09", "completion_date": "2030-03-01", "has_results": false, "last_update_posted_date": "2025-11-19", "last_synced_at": "2026-10-08T07:14:35.002Z", "location_count": 2, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT06072768" } ] }